The investigation of hyaluronic acid and hyaluronidase‐1 levels as tumour marker in larynx cancer
Hakkı Caner İnan  Murat Yener  Nur Buyru  Asuman Çelebi  Mehmet Yilmaz  Nil Çomunoğlu
First published: 17 June 2019 https://doi.org/10.1111/coa.13390
This work was presented as oral presentation at 39th Turkish National Congress of Otorhinolaryngology Head and Neck Surgery, 2017 November 8th, Antalya, Turkey.
Funding information:
This work was supported by Scientific Research Project Coordination Unit of Istanbul University. Project number: 21592, project code TTU‐2016‐21592.

Read the full text
ePDFPDFTOOLS SHARE
Abstract
Objective
The purpose of this study was to investigate the hyaluronic acid (HA) and hyaluronidase‐1 (HYAL‐1) levels in laryngeal cancer patients.

Study design
Prospective, controlled clinical trial.

Setting
University Medical Center.

Participants
Fifty laryngeal squamous cell carcinoma patients and 50 volunteers who gave saliva samples investigated prospectively between 2016 and 2017.

Methods
Hyaluronidase‐1 expression was measured by RT‐PCR in normal and tumour tissue samples; hyaluronic acid values of saliva and tumour tissues were measured by ELISA method.

Results
HYAL‐1 expression increased 2.5‐fold in tumour tissues compared to normal tissues, and the difference was statistically significant (P < 0.001).Mean saliva HA levels were 103.93 ± 69.04 ng/mL and 177.29 ± 98.44 ng/mL in the patients and controls’ saliva specimens, respectively. The difference was not statistically significant (P = 0.657). HA levels were higher in tumour tissue samples than saliva samples, but there was not statistically significant difference between saliva and tumour tissue HA levels.

Conclusion
HYAL‐1 expression in laryngeal squamous cell carcinomas is elevated compared to normal tissues of same patients. Targeting this gene and HA catabolism products may use treatment of larynx cancer in the future.